While some analysts expect the 2025 IPO market to be relatively cool in the near-term, others anticipate more bids than in ...

Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital ...

Traditionally carrying a dire prognosis, the treatment paradigm for multiple myeloma is changing, with CAR T therapies, ...

There are currently no treatments available for celiac disease beyond a gluten-free diet. Several late-phase companies aim to ...

Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...

The conversion of Calquence’s accelerated approval in mantle cell lymphoma comes a day before the drug was listed among the ...

Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...

Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea ...

Drugmakers will have until the end of February to decide whether they want to participate in the second round of Medicare ...

The Phase III CodeBreaK 300 study returned disappointing overall survival data for Lumakras plus Vectibix in metastatic ...

Novartis is locked in a legal back-and-forth with MSN Pharma over alleged patent infringement of its heart failure drug ...